Loratidine versus fexofenadine
Reading File
Searching PubMed
loratadine fexofenadine comparison allergic rhinitis
Finding Sources
Searching PubMed
loratadine fexofenadine antihistamine
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a detailed comparison of loratadine vs fexofenadine across all clinically relevant dimensions:
Loratadine vs Fexofenadine: A Head-to-Head Comparison
Both are second-generation H1 antihistamines used for allergic rhinitis, chronic urticaria, and other IgE-mediated allergic conditions. They are far safer than first-generation agents (no significant sedation, no anticholinergic effects), but they differ meaningfully in pharmacokinetics, potency, and drug interactions.
Mechanism of Action
Both competitively and selectively block peripheral H1 receptors, inhibiting histamine-mediated effects: smooth muscle contraction, increased capillary permeability, itching, sneezing, and rhinorrhea. Second-generation agents like these also modulate the expression of adhesion molecules and reduce eosinophil chemotaxis.
- Lippincott Pharmacology, p. 1313 - 1316
Pharmacokinetics
| Property | Loratadine | Fexofenadine |
|---|---|---|
| Brand name | Claritin | Allegra |
| Oral absorption | Rapid; peak ~1-2 h | Peak ~2-3 h |
| Half-life | 8-24 h (variable, hepatic-dependent) | ~14 h (stable) |
| Metabolism | Hepatic via CYP 3A4 → active metabolite desloratadine | Minimal hepatic metabolism |
| Excretion | Hepatic/renal | Largely unchanged in feces (biliary); also P-gp substrate |
| Active metabolite | Yes - desloratadine | No |
| Dose adjustment in hepatic impairment | Required (longer half-life, accumulation risk) | Not required |
| Dose adjustment in renal impairment | Minimal adjustment needed | Adjustment recommended (renally cleared too) |
- Fitzpatrick's Dermatology, p. 3482; Lippincott Pharmacology, p. 1314
Potency (Wheal-and-Flare Suppression)
In a head-to-head single-dose study, skin responses to intradermal histamine were suppressed as follows:
Cetirizine > Fexofenadine > Loratadine
Similarly, fexofenadine 180 mg and levocetirizine 5 mg are more potent than desloratadine 5 mg in suppressing histamine skin reactions.
This means fexofenadine is pharmacodynamically more potent than loratadine at standard doses.
- Fitzpatrick's Dermatology, p. 3482
CNS / Sedation Profile
| Property | Loratadine | Fexofenadine |
|---|---|---|
| CNS penetration | Low (second-generation) | Very low - virtually no CNS penetration |
| Sedation | Rare at standard doses; some reports at higher doses | Least sedating of the second-generation agents |
| Driving impairment | Minimal | Negligible |
Fexofenadine does not readily cross the blood-brain barrier partly due to active efflux by P-glycoprotein, making it the least sedating antihistamine available.
Drug Interactions
| Property | Loratadine | Fexofenadine |
|---|---|---|
| CYP 3A4 substrate | Yes | No |
| CYP inhibitors (azoles, macrolides, etc.) | Can raise loratadine levels | Minimal CYP interaction |
| Fruit juice (grapefruit, orange, apple) | Less clinically significant | Reduces fexofenadine absorption - avoid co-administration (inhibits OATP transporters) |
| P-glycoprotein | Not significant | Substrate - ketoconazole and erythromycin increase fexofenadine levels (though not clinically dangerous) |
Fexofenadine's main interaction is with fruit juices and P-gp inhibitors - not CYP450 enzymes. Loratadine carries more hepatic drug interaction potential due to CYP 3A4 involvement.
Dosing
| Loratadine | Fexofenadine | |
|---|---|---|
| Standard adult dose | 10 mg once daily | 120-180 mg once daily (allergic rhinitis: 120 mg; urticaria: 180 mg) |
| Duration of action | 24 h | 24 h |
| Food effect | Minimal | Take on empty stomach or with water - fruit juice reduces absorption significantly |
| Available formulations | Oral tablet, syrup, ODT | Oral tablet, syrup |
Indications
Both drugs are indicated for:
- Seasonal and perennial allergic rhinitis (sneezing, rhinorrhea, itching - not nasal congestion)
- Chronic idiopathic urticaria
- Other allergic skin conditions
Neither drug is useful for bronchial asthma, since histamine is only one of many mediators involved.
- Lippincott Pharmacology, p. 1313
Special Populations
| Population | Loratadine | Fexofenadine |
|---|---|---|
| Pregnancy | Category B; generally considered safe | Category C; limited data |
| Hepatic impairment | Reduce dose or frequency | No dose adjustment needed |
| Renal impairment | Minimal concern | Dose reduction recommended (accumulation risk) |
| Elderly | Second-gen preferred over first-gen; safe | Similarly safe; non-CNS profile advantageous |
Summary: When to Choose Which
| Scenario | Preferred Agent |
|---|---|
| Maximum antihistamine effect needed | Fexofenadine (more potent) |
| Safety-critical occupation (pilot, surgeon, driver) | Fexofenadine (lowest sedation risk) |
| Hepatic impairment | Fexofenadine (no hepatic metabolism) |
| Patient on many CYP 3A4-interacting drugs | Fexofenadine (avoids hepatic interaction) |
| Renal impairment | Loratadine (less renal-dependent) |
| Cost/generic availability | Loratadine (widely available OTC, cheaper) |
| Active metabolite benefit | Loratadine → desloratadine (longer effective duration in some) |
Bottom line: Fexofenadine has an edge in potency, sedation safety, and hepatic drug interaction profile. Loratadine is a reliable, widely-used option with good tolerability, but requires dose caution in hepatic disease and has a somewhat lower potency ceiling.
Sources: Fitzpatrick's Dermatology, p. 3481-3483; Lippincott Illustrated Reviews: Pharmacology, pp. 1305-1316; Goldman-Cecil Medicine, block 58.
This is a shared conversation. Sign in to Orris to start your own chat.